Indeed, in a case report38, olaparib, a PARP inhibitor, exhibited significant efficacy in a patient with ovarian CS harboring a germline mutation in RAD51D, a gene involved in HR repair, supporting the use of PARP inhibitors in patients with CS with HRD. This evidence concerns the gene RAD51D and hypoparathyroidism-retardation-dysmorphism syndrome.